Technology

The French pharmaceutical market is forecast to grow at a "tepid" CAGR of 0.7% from $46.2 billion in 2014 to $48.2 billion by 2020, according to GlobalData.

Pharma and healthcare are among the many areas being viewed with increasing attention inside and outside Greece, following the victory in the country’s elections of the radical left-wing, anti-austerity Syriza party.

Findings from the joint report on the occurrence of antimicrobial resistance in bacteria from humans and food-producing animals.

The European Hantavirus diagnostics market is growing at a CAGR of 5.8 percent, outperforming the U.S. market, which registered 3.7 percent.

GlaxoSmithKline (GSK) announced on January 26 that it will freeze vaccine prices for Gavi-eligible countries for up to 10 years after the country graduates from Gavi support.

Glaxo SmithKline (GSK) has announced that Sir Philip Hampton has been appointed Chairman of the Nominations Committee, effective today (January 27).

Franz Humer, former CEO and chairman of Roche, has joined BIAL, Portugal's largest pharma company, as a non-executive board member.

CPhI Worldwide is launching an international advisory board.

With the FDA approving an all-time record number of orphan drugs during 2014, the pricing of these treatments is set to come under increased scrutiny.

Investigators and sponsors of clinical trials will have to make more detailed data available following study completion, according to a new report from an Institute of Medicine (IOM) expert panel.

Healthcare and pharma executives have recovered their optimism in the past year, according to an EIU survey.

Pharm Exec’s annual report highlights the key scientific, commercial, and reputational trends shaping the industry in the year ahead.

Frost & Sullivan has released its "Drug Launch and Phase 3 Trial Watch List for Top Therapy Areas for 2015".

WHO's tuberculosis program leader and the CFO of Ultragenyx jojn Board of Directors.

Richard Bergström, Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA) has called for "homogenization of European HTA bodies and regulation"

CVS confirmed this week that it will exclusively offer Gilead's Harvoni and Sovaldi to members through its CVS/Caremark commercial, exchange, Medicare Part D, and Medicaid formularies.

Oxford University doctors and scientists have begun the first safety trial of Janssen's experimental Ebola vaccine in the UK.

Big Pharma and foreign investors are "flocking" to Turkey to capitalize on its encouraging economic policies, according to new analysis from Frost & Sullivan.

Isis Pharmaceuticals has announced that it has entered into a collaboration with Janssen Biotech to develop three antisense drugs to treat autoimmune disorders of the gastrointestinal (GI) tract.

The Colorectal Cancer (CRC) therapeutics market in Asia-Pacific (APAC) is set to increase in value, from $1.9 billion in 2013 to $2.9 billion by 2020 (a Compound Annual Growth Rate [CAGR] of 6.5%), says a new report from GBI Research.

Two of the industry's most influential conferences occurred within weeks of each other this autumn – TEDMED and Health 2.0. Bill Drummy reviews both events.

Data analytic strategies can help companies capitalise on personalised medicine, writes Jill E. Sackman and Michael Kuchenreuther.

Will the FDA's social media guidelines help your digital strategy to take off? Check out what they say - and what they mean- in the latest issue of Pharm Exec Global Digest

Three medical affairs experts - Sean Turbeville, David A. Wells, and Charles Wolfus - review the capabilities of Google’s latest technology for delivering information to healthcare professionals in the field.

The med-tech industry has a legacy of creating life-extending products while rewarding investors. This connection between innovation and profitability has been a key driver. But, writes Doug Mowen, change is underway.